Search hospitals
>
Indiana
>
Indianapolis
Indiana University School of Medicine
Claim this profile
Indianapolis, Indiana 46202
Global Leader in Alzheimer's Disease
Global Leader in Dementia
Conducts research for Chronic Kidney Disease
Conducts research for Nonalcoholic Steatohepatitis
Conducts research for Type 2 Diabetes
232 reported clinical trials
27 medical researchers
Summary
Indiana University School of Medicine is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Alzheimer's Disease, Dementia, Chronic Kidney Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes and other specialties. Indiana University School of Medicine is involved with conducting 232 clinical trials across 436 conditions. There are 27 research doctors associated with this hospital, such as Monika Fischer, Jared Brosch, Raj Vuppalanchi, MD, and Linda DiMeglio, MD.
Area of expertise
Alzheimer's Disease
Indiana University School of Medicine has run 30 trials for Alzheimer's Disease. Some of their research focus areas include:
Dementia
Indiana University School of Medicine has run 13 trials for Dementia. Some of their research focus areas include:
Top PIs
Monika Fischer
Indiana University
3 years of reported clinical research
Jared Brosch
Indiana University School of Medicine
5 years of reported clinical research
Raj Vuppalanchi, MD
Indiana University School of Medicine
1 year of reported clinical research
Linda DiMeglio, MD
Indiana University - Riley Hospital for Children
3 years of reported clinical research
Clinical Trials running at Indiana University School of Medicine
Alzheimer's Disease
Dementia
Prostate Cancer
Sickle Cell Disease
Phenylketonuria
Bladder Cancer
Rheumatoid Arthritis
Aortic Dissection
Post-Traumatic Stress Disorder
Kidney Failure
Gantenerumab
for Alzheimer's Disease
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting
0 awards
Phase 2 & 3
10 criteria
LY3954068
for Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. Participants will have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period.
Recruiting
0 awards
Phase 1
Remternetug
for Alzheimer's Disease
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting
0 awards
Phase 2 & 3
2 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Indiana University School of Medicine?
Indiana University School of Medicine is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Alzheimer's Disease, Dementia, Chronic Kidney Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes and other specialties. Indiana University School of Medicine is involved with conducting 232 clinical trials across 436 conditions. There are 27 research doctors associated with this hospital, such as Monika Fischer, Jared Brosch, Raj Vuppalanchi, MD, and Linda DiMeglio, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.